Download Current Status and Future of Anti-Cancer Targeted Therapies

V InterAmerican Oncology Conference
'Current Status and Future of Anti-Cancer Targeted Therapies'
Universidad Católica Argentina
October 10-11, 2013
Buenos Aires, Argentina
FIRST ANNOUNCEMENT
The Fifth Conference of IAOC “Current Status and Future of Anti-Cancer Targeted Therapies” will
be held in Buenos Aires, Argentina in October 10th and 11th, 2013.
An outstanding faculty of speakers from the United States and Europe has committed in this meeting.
The conference agenda will focus on new translational advances in the treatment of cancer as well as
provide updates of conventional therapies for a number of the most common tumor types. The meeting
objectives are designed to introduce the audience to the latest information on targeted therapies,
immunotherapies and emerging treatments in early development. The major emphasis will be on clinical
aspects of cancer treatment in the 21st century with discussion of significant scientific advances underlying
the novel approaches still in preclinical development.
This meeting is the primary opportunity for oncologists and cancer related health workers to participate in
a conference focusing on novel targeted therapies and other treatment advances which are changing the
face of cancer care.
CO- CHAIRS
Román Perez Soler, New York, USA
Carlos L. Arteaga, Nashville, USA
ORGANIZING COMMITTEE
Román Pérez Soler, New York, USA.
Carlos L. Arteaga, Nashville, USA.
Andrea Blanco, Buenos Aires, Argentina.
SCIENTIFIC COMMITTEE
Alex Adjei, M.D., Ph.D., Roswell Park Cancer Institute, Buffalo, New York, USA
Kenneth C. Anderson, M.D., Dana-Farber Cancer Institute Boston, Massachusetts, USA
Carlos L. Arteaga, M.D., Vanderbilt University School of Medicine, Nashville, USA
Hernán Cortes Funes, M.D., Hospital Universitario "12 de Octubre", Madrid, Spain
Roman Perez Soler, M.D., Albert Einstein College of Medicine, Bronx, New York, USA
Josep Tabernero, M.D., Vall d’Hebron University Hospital, Barcelona, Spain
FACULTY (PROVISIONARY)
Alex A. Adjei, M.D., Ph.D.
Professor and Chair, Department of Medicine
Katherine Anne Gioia Chair in Cancer Medicine
Roswell Park Cancer Institute
Buffalo, New York, USA
Kenneth C. Anderson, M.D.
Kraft Family Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
Carlos L. Arteaga, M.D.
Professor of Medicine and Cancer Biology
Associate Director for Clinical Research
Director, Breast Cancer Program
Vanderbilt –Ingram Cancer Center
Nashville, Tennessee, USA
Joaquim Bellmunt M.D., Ph.D.
NAQAA Professor of Medicine
Pompeu Fabra University
Section Chief, Solid Tumor Oncology (GU & GI)
Medical Oncology Service, Hospital del Mar
Barcelona, Spain
Robert L. Coleman, M.D.
Professor & Vice Chair, Clinical Research
Department of Gynecologic Oncology
& Reproductive Medicine
University of Texas, M.D. Anderson Cancer Center
Houston, Texas, USA
Jorge Cortes, M.D.
Professor of Medicine
Chief, CML & AML Sections
Deputy Chair, Department of Leukemia
MD Anderson Cancer Center
Houston, Texas, USA
Hernán Cortés Funes, M.D.
Department of Medical Oncology
Hospital Universitario "12 de Octubre"
Madrid, Spain
John P. Leonard, M.D.
Richard T. Silver Distinguished Professor
of Hematology and Medical Oncology
Associate Dean for Clinical Research
Chief, Lymphoma Service,
Vice Chairman for Clinical Research
Weill Cornell Cancer Center
New York, New York, USA
2
FACULTY (PROVISIONARY)
Román Pérez-Soler, M.D.
Chairman, Department of Oncology
Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, New York, USA
Daniel P. Petrylak, M.D.
Director, Genitourinary Oncology Program
Co Director, Signal Transduction Program
Yale University Cancer Center
New Haven, Connecticut, USA
Jeffrey A. Sosman M.D.
Professor of Medicine
Ingram Professor for Cancer Research
Vanderbilt University Medical Center
Division of Hematology/Oncology
Nashville, Tennessee, USA
Josep Tabernero, M.D.
Chairman Medical Oncology Department
Vall d’Hebron University Hospital
Barcelona, Spain
Vicente Valero, M.D., F.A.C.P.
Professor of Medicine, Deputy Chairman
Department of Breast Medical Oncology
University of Texas M.D. Anderson Cancer Center
Houston, Texas, USA
John J. Wright, M.D., Ph.D.
Associate Branch Chief
Investigational Drug Branch
National Cancer Institute
Bethesda, Maryland, USA
3
PRELIMINARY PROGRAM
NEW ANTICANCER THERAPIES
 Promising Novel Agents in Early Clinical Trials:
Alex A. Adjei, Buffalo, USA
 New Drug Development at the NCI:
John J. Wright, Bethesda, USA
 Use of Molecular Markers to Select Patients:
Román Pérez Soler, New York, USA
 PI3K/TOR Pathway Inhibitors:
Carlos L. Arteaga, Nashville, USA
 Targeted Therapy for Melanoma:
Jeffrey A. Sosman, Nashville, USA
WOMEN´S CANCER
 New Drugs in Breast Cancer:
Vicente Valero, Houston, USA
 Current and Future Treatments in Breast Cancer:
Hernán Cortés Fúnes, Madrid, Spain
 Hormonal Therapies and Combinations to Bypass Resistance:
Carlos L. Arteaga, Nashville, USA
 New Therapies in Ovarian Cancer:
Robert L. Coleman, Houston, USA
GU AND GI CANCER
 New Targeted Therapies in Prostate and Renal Cancer:
Daniel P. Petrylak, New Haven, USA
 Advances in the Management of Metastatic Urothelial Cancer:
Joaquim Bellmunt, Barcelona, Spain
 Treatment for Advanced Colorectal Cancer:
Josep Tabernero, Barcelona, Spain
LUNG CANCER
 New Targets in Lung Cancer:
Alex A. Adjei, New York, USA
 Advances in Frontline Treatment:
Román Pérez Soler, New York, USA
4
PRELIMINARY PROGRAM
HEMATOLOGICAL MALIGNANCIES
 Lymphoma:
John P. Leonard, New York, USA
 Multiple Myeloma:
Kenneth C. Anderson, Boston, USA
 Leukemia:
Jorge Cortes, Houston, USA
CONFERENCE SECRETARIAT AND INFORMATION
E-mail: [email protected]
Web: www.oncologyconferences.com.ar
5